Spero Therapeutics, Inc. (SPRO) SEC Filing 8-K Material Event for the period ending Thursday, October 3, 2019

Spero Therapeutics, Inc.

CIK: 1701108 Ticker: SPRO

View differences made from one to another to evaluate Spero Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Spero Therapeutics, Inc..


Assess how Spero Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Spero Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Material Contracts, Statements, Certifications & more

Spero Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: SPRO
CIK: 1701108
Form Type: 8-K Corporate News
Accession Number: 0001193125-19-261358
Submitted to the SEC: Thu Oct 03 2019 12:19:06 PM EST
Accepted by the SEC: Thu Oct 03 2019
Period: Thursday, October 3, 2019
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: